Literature DB >> 17199574

The risk for cutaneous malignant melanoma, melanoma in situ and intraocular malignant melanoma in relation to tobacco use and body mass index.

A Odenbro1, P Gillgren, R Bellocco, P Boffetta, N Håkansson, J Adami.   

Abstract

BACKGROUND: The incidence of cutaneous malignant melanoma (CMM) and melanoma in situ (MIS) has been increasing during the last 50 years. Malignant melanoma (MM) is also the most common intraocular malignancy (IMM). Besides ultraviolet radiation, the cause of these tumours is largely unknown.
OBJECTIVES: We designed a study to examine the effect of body mass index (BMI) and tobacco use on the risk for MM and MIS.
METHODS: Analyses were performed on a nationwide cohort of 339 802 Swedish construction workers. Exposure information was collected prospectively by questionnaires combined with personal interviews.
RESULTS: Follow up yielded a total of 7 663 400 person-years during which 1639 workers developed MM/MIS. The risk for MM/MIS was reduced in current or previous smokers compared with those who had never smoked, both when analysing all smoking tobacco products combined and when analysing cigarette and pipe smokers separately. The risk was further diminished with longer duration of smoking and greater quantity of tobacco smoked. The effect was more evident in CMM/MIS than in IMM. Snuff taking conferred a decreased risk for CMM/MIS, and a BMI over normal weight range conferred an increased risk for CMM.
CONCLUSIONS: Tobacco smoking was found to be inversely associated with the risk for CMM and MIS. The mechanism of action is unknown but it has been suggested to be due to the immune suppressive effect that tobacco exerts which would be protective against deleterious immune reactions caused by, for example, the sun. Neither is the mechanism behind the higher risk for CMM due to being overweight known. One hypothesis is that it is an effect of a hormonal imbalance. Further studies are required to elucidate these mechanisms.

Entities:  

Mesh:

Year:  2007        PMID: 17199574     DOI: 10.1111/j.1365-2133.2006.07537.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  20 in total

1.  Cigarette smoking and malignant melanoma: a case-control study.

Authors:  Maria C Kessides; Lee Wheless; Judith Hoffman-Bolton; Sandra Clipp; Rhoda M Alani; Anthony J Alberg
Journal:  J Am Acad Dermatol       Date:  2010-03-23       Impact factor: 11.527

Review 2.  Systematic review of the relation between smokeless tobacco and cancer in Europe and North America.

Authors:  Peter N Lee; Jan Hamling
Journal:  BMC Med       Date:  2009-07-29       Impact factor: 8.775

3.  Critique of the International Agency for Research on Cancer's meta-analyses of the association of sunbed use with risk of cutaneous malignant melanoma.

Authors:  William B Grant
Journal:  Dermatoendocrinol       Date:  2009-11

4.  The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma.

Authors:  Maris S Jones; Peter C Jones; Stacey L Stern; David Elashoff; Dave S B Hoon; John Thompson; Nicola Mozzillo; Omgo E Nieweg; Dirk Noyes; Harald J Hoekstra; Jonathan S Zager; Daniel F Roses; Alessandro Testori; Brendon J Coventry; Mark B Smithers; Robert Andtbacka; Doreen Agnese; Erwin Schultz; Eddy C Hsueh; Mark Kelley; Schlomo Schneebaum; Lisa Jacobs; Tawnya Bowles; Mohammed Kashani-Sabet; Douglas Johnson; Mark B Faries
Journal:  Ann Surg Oncol       Date:  2017-02-21       Impact factor: 5.344

5.  Smoking and risk of skin cancer: a prospective analysis and a meta-analysis.

Authors:  Fengju Song; Abrar A Qureshi; Xiang Gao; Tricia Li; Jiali Han
Journal:  Int J Epidemiol       Date:  2012-10-11       Impact factor: 7.196

6.  Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data.

Authors:  Juliette A Randerson-Moor; John C Taylor; Faye Elliott; Yu-Mei Chang; Samantha Beswick; Kairen Kukalizch; Paul Affleck; Susan Leake; Sue Haynes; Birute Karpavicius; Jerry Marsden; Edwina Gerry; Linda Bale; Chandra Bertram; Helen Field; Julian H Barth; Isabel Dos Santos Silva; Anthony Swerdlow; Peter A Kanetsky; Jennifer H Barrett; D Timothy Bishop; Julia A Newton Bishop
Journal:  Eur J Cancer       Date:  2009-07-15       Impact factor: 9.162

7.  Competing risk bias to explain the inverse relationship between smoking and malignant melanoma.

Authors:  Caroline A Thompson; Zuo-Feng Zhang; Onyebuchi A Arah
Journal:  Eur J Epidemiol       Date:  2013-05-23       Impact factor: 8.082

8.  Role of BMI and hormone therapy in melanoma risk: a case-control study.

Authors:  Vincenzo De Giorgi; Alessia Gori; Imma Savarese; Antonietta D'Errico; Federica Scarfì; Federica Papi; Vincenza Maio; Piero Covarelli; Daniela Massi; Sara Gandini
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-13       Impact factor: 4.553

9.  Family history of melanoma and Parkinson disease risk.

Authors:  X Gao; K C Simon; J Han; M A Schwarzschild; A Ascherio
Journal:  Neurology       Date:  2009-10-20       Impact factor: 9.910

10.  PPARbeta activation inhibits melanoma cell proliferation involving repression of the Wilms' tumour suppressor WT1.

Authors:  Jean-François Michiels; Christophe Perrin; Nathalie Leccia; Daniela Massi; Paul Grimaldi; Nicole Wagner
Journal:  Pflugers Arch       Date:  2010-01-12       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.